SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/50284"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/50284" > Economic implicatio...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003901naa a2200673 4500
001oai:gup.ub.gu.se/50284
003SwePub
008240910s2005 | |||||||||||000 ||eng|
024a https://gup.ub.gu.se/publication/502842 URI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Caro, J. J.4 aut
2451 0a Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial
264 1c 2005
520 a BACKGROUND: The MERIT-HF trial demonstrated improved survival and fewer hospitalizations for worsening heart failure with extended-release (ER) metoprolol succinate in patients with heart failure. This study sought to estimate the economic implications of this trial from a US perspective. METHODS AND RESULTS: A discrete event simulation was developed to examine the course of patients with heart failure. Characteristics of the population modeled, probabilities of hospitalization and death with standard therapy, and risk reductions with ER metoprolol succinate were obtained from Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) and evaluated in weekly cycles. Direct medical costs were estimated from US databases in 2001 US dollars. Uncertainty in inputs was incorporated and analyses were carried out to estimate events prevented total and net costs. The model predicts that ER metoprolol succinate will prevent approximately 7 deaths and 15 hospitalizations from heart failure per 100 patients over 2 years. Compared with standard therapy alone, this translates to a cost reduction between $395 and $1112 per patient, depending on whether the costs of hospitalizations for other causes are included. Savings were maintained in 90% of the simulations. CONCLUSION: This analysis predicts that the positive effect of ER metoprolol succinate on mortality and morbidity demonstrated in MERIT-HF leads to substantial savings.
653 a Adrenergic beta-Antagonists/administration & dosage/economics/*therapeutic
653 a use
653 a Adult
653 a Aged
653 a Aged
653 a 80 and over
653 a Cost-Benefit Analysis
653 a Delayed-Action Preparations
653 a Female
653 a Heart Failure
653 a Congestive/*drug therapy/*economics/mortality
653 a Hospital Costs
653 a Hospital Mortality
653 a Hospitalization/*economics/statistics & numerical data
653 a Humans
653 a Male
653 a 
653 a derivatives/economics/therapeutic use
653 a Middle Aged
653 a Models
653 a Econometric
653 a Prospective Studies
653 a Randomized Controlled Trials
653 a Reproducibility of Results
653 a Survival Analysis
653 a Treatment Outcome
653 a United States
700a Migliaccio-Walle, K.4 aut
700a O'Brien, J. A.4 aut
700a Nova, W.4 aut
700a Kim, J.4 aut
700a Hauch, O.4 aut
700a Hillson, E.4 aut
700a Wedel, H.4 aut
700a Hjalmarson, Åke,d 1937u Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory4 aut0 (Swepub:gu)xhjala
700a Gottlieb, S.4 aut
700a Deedwania, P. C.4 aut
700a Wikstrand, John,d 1938u Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory4 aut0 (Swepub:gu)xwikjo
710a Göteborgs universitetb Hjärt-kärlinstitutionen4 org
773t J Card Failg 11:9, s. 647-56q 11:9<647-56x 1071-9164
8564 8u https://gup.ub.gu.se/publication/50284

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy